#1 Clinical Trials Search in Europe

Dupilumab

This article explores the use of Dupilumab, a biologic medication, in various clinical trials. Dupilumab is being studied for its effectiveness in treating conditions such as eosinophilic esophagitis, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma. These trials aim to assess the drug’s efficacy, safety, and long-term outcomes in different patient populations.

Table of Contents

What is DUPILUMAB?

DUPILUMAB, also known by its brand name DUPIXENT[1], is a medication used to treat various inflammatory conditions. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-made proteins designed to target specific parts of the immune system[2]. DUPILUMAB works by blocking the action of certain proteins in the body that contribute to inflammation.

What Conditions Does DUPILUMAB Treat?

DUPILUMAB is approved to treat several conditions characterized by type 2 inflammation, including:

  • Atopic Dermatitis (Eczema): A chronic skin condition causing itchy, inflamed skin[2][3]
  • Asthma: A respiratory condition causing breathing difficulties[1]
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A condition where the sinuses are inflamed and nasal polyps develop[4][5]
  • Eosinophilic Esophagitis (EoE): An allergic condition affecting the esophagus[6]

How Does DUPILUMAB Work?

DUPILUMAB works by targeting a specific part of the immune system involved in inflammation. It blocks the action of two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13)[7]. These proteins play a key role in type 2 inflammation, which is involved in conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. By blocking these proteins, DUPILUMAB helps reduce inflammation and alleviate symptoms associated with these conditions.

How is DUPILUMAB Administered?

DUPILUMAB is typically administered as a subcutaneous injection, which means it’s injected under the skin. The dosing schedule can vary depending on the condition being treated:

  • For most conditions, treatment often starts with a higher initial dose (called a loading dose) of 600 mg, followed by 300 mg every two weeks[2][5]
  • In some cases, such as for atopic dermatitis, a dose of 300 mg may be given weekly[6]
  • The medication can be administered by a healthcare professional, or patients may be trained to self-administer the injections at home[6]

Effectiveness of DUPILUMAB

Clinical trials and real-world studies have shown DUPILUMAB to be effective in treating various inflammatory conditions:

  • Atopic Dermatitis: DUPILUMAB has been shown to significantly improve skin clearance, reduce itching, and enhance quality of life in patients with moderate-to-severe atopic dermatitis[2]
  • Asthma: The medication has demonstrated effectiveness in improving lung function, reducing asthma exacerbations, and decreasing the need for oral corticosteroids in patients with moderate-to-severe asthma[1]
  • Chronic Rhinosinusitis with Nasal Polyps: DUPILUMAB has shown to reduce nasal polyp size, improve nasal congestion, and enhance the sense of smell in patients with CRSwNP[4]
  • Eosinophilic Esophagitis: Studies have shown that DUPILUMAB can improve symptoms and reduce inflammation in the esophagus in patients with EoE[6]

Potential Side Effects

Like all medications, DUPILUMAB can cause side effects, although not everyone experiences them. Common side effects may include:

  • Injection site reactions (redness, swelling, or itching at the injection site)
  • Eye and eyelid inflammation
  • Cold sores on the mouth or lips
  • Headache

More serious side effects are rare but can occur. It’s important to discuss potential side effects with your healthcare provider[4].

Ongoing Research and Future Directions

Research on DUPILUMAB is ongoing, with several studies exploring its potential in various areas:

  • Long-term effectiveness and safety: Studies are being conducted to assess the long-term outcomes of DUPILUMAB treatment in conditions like chronic rhinosinusitis with nasal polyps[4]
  • Combination therapies: Research is exploring the potential benefits of combining DUPILUMAB with other treatments, such as allergen immunotherapy for allergic rhinoconjunctivitis[8]
  • Ethnic differences in response: Studies are investigating how DUPILUMAB’s effectiveness may vary among different ethnic groups[7]
  • Dose optimization: Research is being conducted to determine if lower doses or extended dosing intervals can maintain effectiveness in some patients[9]
  • Early-onset effects: Studies are exploring the rapid changes that occur in the body soon after starting DUPILUMAB treatment[5]

These ongoing studies aim to further improve our understanding of DUPILUMAB and optimize its use in treating various inflammatory conditions.

Aspect Details
Conditions Studied Eosinophilic Esophagitis, Atopic Dermatitis, Chronic Rhinosinusitis with Nasal Polyps, Asthma
Administration Subcutaneous injection, typically 300mg every 2 weeks or as prescribed
Primary Outcomes Symptom improvement, changes in disease severity scores, quality of life assessments, inflammatory biomarkers
Study Designs Randomized controlled trials, open-label studies, long-term observational studies
Duration Varies from several weeks to up to 3 years for long-term studies
Safety Monitoring Adverse event reporting, regular check-ups, blood tests, and imaging studies as needed
Combination Therapies Some trials explore Dupilumab in combination with other treatments like immunotherapy or phototherapy
Patient Populations Adults and in some cases adolescents, with specific inclusion criteria based on disease severity and previous treatments

FAQ

  • What conditions is Dupilumab being studied for in clinical trials? Dupilumab is being studied for multiple conditions including eosinophilic esophagitis, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma.
  • How is Dupilumab administered in these trials? In most trials, Dupilumab is administered as a subcutaneous injection. The dosage and frequency may vary, but common regimens include 300mg every two weeks or an initial loading dose followed by regular injections.
  • What are some of the primary outcomes being measured in Dupilumab trials? Primary outcomes vary by condition but often include measures of symptom improvement, changes in disease severity scores, quality of life assessments, and specific biomarkers related to inflammation.
  • Are there any studies looking at long-term effects of Dupilumab? Yes, several studies are designed to assess long-term outcomes of Dupilumab treatment, with some trials following patients for up to 3 years to evaluate effectiveness and safety over time.
  • Are there any studies comparing Dupilumab to other treatments? While many studies focus on Dupilumab alone, some trials compare it to placebo or investigate its use in combination with other treatments, such as allergen immunotherapy or phototherapy.

Ongoing Clinical Trials on Dupilumab

  • Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Greece Hungary Ireland Romania +1

  • Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +3

  • Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study Comparing Dupilumab and Mepolizumab for Treating Chronic Rhinosinusitis with Nasal Polyps in Danish Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Reducing Dupilumab Dose for Patients with Controlled Atopic Eczema

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Dupilumab for Treating Nummular Eczema in Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Dupilumab: A biologic medication that works by blocking interleukin-4 and interleukin-13, two key proteins involved in type 2 inflammation associated with various allergic and inflammatory conditions.
  • Eosinophilic Esophagitis (EoE): A chronic allergic condition where the esophagus becomes inflamed, often leading to difficulty swallowing and food getting stuck.
  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin, also known as eczema.
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A condition where the sinuses are inflamed for 12 weeks or longer, accompanied by growths in the nasal passages called polyps.
  • Subcutaneous Injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a drug against no treatment.
  • Biomarker: A measurable indicator of a biological state or condition, often used to assess the effectiveness of a treatment.
  • SNOT-22: Sino-Nasal Outcome Test, a patient-reported measure of sino-nasal health status.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities, often used as an outcome in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT04287621
  2. https://clinicaltrials.gov/study/NCT03720470
  3. https://clinicaltrials.gov/study/NCT05285839
  4. https://clinicaltrials.gov/study/NCT04959448
  5. https://clinicaltrials.gov/study/NCT06188871
  6. https://clinicaltrials.gov/study/NCT06352073
  7. https://clinicaltrials.gov/study/NCT05268107
  8. https://clinicaltrials.gov/study/NCT04502966
  9. https://clinicaltrials.gov/study/NCT06004986